Bioling, a health technology company developing wearable biosensors for metabolic health has announced it has secured $100m in funding for a wearable patch that evaluates glucose levels and provides insights into metabolic health for individuals with Type 2 diabetes who are not on insulin.
The patch uses small electrochemical sensors to measure glucose levels from the intradermal space just beneath the skin’s surface. It has not yet been cleared or approved by the FDA.
“Our team has spent the last decade developing a biosensor platform designed to inspire healthier living by providing context around a person’s metabolic health” said Rich Yang, CEO of Biolinq. “This financing will bolster Biolinq’s commercial readiness efforts while we pursue regulatory approval for the first intradermal glucose sensor that incorporates activity and sleep information into a single wearable device.”
To find out more, CLICK HERE.
